TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: mean change in modified total Sharp score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of overall infections
Endpoint domain: Adverse events/effects
Primary endpoint: Peri-implant mucositis (PIM) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Peri-implantitis (PI) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in prealbumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of pulpal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flow-mediated dilation (FMD%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative Percocet consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: anterior tooth retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maxillary molar mesialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mandibular plane angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-disclosure rates
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Receipt of advice
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Non-positive feedback
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time required for nontreatment trial activities
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost per enrolled subject for industry-sponsored trial
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: gait cycle modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of adjustment to the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body size-specific lung dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiological outcomes
Primary endpoint: Effective dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiological outcomes
Primary endpoint: Performance speed in posttest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to conceive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Psychological Status (PS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: overall visit satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maintenance of sinus rhythm (SR) at 1 week postcardioversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: P-wave energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of remission from MDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean fluorescence and area of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of significant others in social networks
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: clinical outcomes at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak concentration (Cmax, ng/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC0‐ infinity, ng h/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the maximal concentration (tmax, h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of dizziness VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anemia decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cumulative incidence of all prostate cancers
Endpoint domain: Mortality/survival
Primary endpoint: cumulative incidence of interval cancer
Endpoint domain: Mortality/survival
Primary endpoint: cumulative incidence of aggressive interval cancer
Endpoint domain: Mortality/survival
Primary endpoint: fine motor coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: visuomotor integration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: visual perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: visuospatial organization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in histological liver damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in AST levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swollen Joint Count (SJC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tender Joint Count (TJC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma alpha‐tocopherol and ascorbic concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TAOC (Total Antioxidant Capacity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP concentrations within 90 days postinfarct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glottic exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acyclovir C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Acyclovir AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Insulin incremental area under curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Between observer repeatability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0‐24 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cmax,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma t1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active decision making involvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Total time to complete basketball-specific movement drills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of shots made during DEH versus EUH control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total chest tube drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: need for additional postoperative procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: core vitrectomy duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Scores on the 3MS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Scores on the IWQOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: First-phase insulin secretion (ISR) relative to glucose at 0-0.5 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fasting plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak insulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: reduction in symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving HbA(1c) < 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AH frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AH severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS total and general subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CA 125 serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: persistent symptoms of ulcer disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total maternal weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary energy intake during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haematocrit values at 1 and 6 weeks postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of self-reported AV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of AV by clinical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in CMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general fatigue after a typical working day
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: influence on own work
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Healing of ulcers and erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: attachment levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: index values for plaque and bleeding on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Production of prostacyclin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Excretion of prostacyclin metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of adverse reactions using tourniquets
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in number of anxiety diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical severity of diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self and parent reported anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients treated with thrombolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of air leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intercostal chest drainage time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MPA AUC values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMPA AUC values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of endodontic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in symptoms on the PARS5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in symptoms on the PARS6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission status based on PARS5 and PARS6 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Copper levels decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Creatinine levels decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MBI and mRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to completion
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Very high intratumoral signal intensity on T2‐weighted MR images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Inhibition of amygdala responses to fear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of emotional bias in perception of ambiguous faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean OLP (cmH2O)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tidal volume (ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of first attempt insertion (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venous FFA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: venous dilution of palmitate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: metabolic clearance rate of acyl ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: undetectable HBV DNA rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Receptive language scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expressive vocabulary (per parent report)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of consonants correct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRC screening prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in HbA1c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response rate to moclobemide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of moclobemide
Endpoint domain: Adverse events/effects
Primary endpoint: TAM range of burned finger joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip strength of burned hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SAS scores (psychological anxiety)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: median endoxifen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients reaching target fasting blood glucose (<120 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: elevation of urinary NAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Median duration of partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median overall duration of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wounded area size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epithelialization score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI increase at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minimum effective anesthetic concentration of mepivacaine (ED(50))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Block rate of lateral femoral cutaneous and obturator nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative analgesic supplementation requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to use female condom
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Use of female condom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diastolic blood pressure area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of measured symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of days with moderate to severe headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of acute dermatitis of grade 2 or higher
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Restoration of vaginal pH to levels normally seen in fertile women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferation of the vaginal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of intraoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PaO2/FiO2 ratio (P/F) < 300
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: decreased urinary retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incremental area under the curve (IAUC) for insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success in activating a computer using a hand switch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in activating a computer using a head switch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder and rectal doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of IFN-related genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gene expression of cholesterol biosynthesis pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CD63 upregulation suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD203c upregulation suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of acetylcholine-induced vasoconstriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Probability of biochemical relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Cumulative duration of normalized ALT periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Abstinence from smoking at 18 months post-quit date
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discomfort/pain from peri-implant probing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of leg movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influenza vaccination coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of intestinal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CDAI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IBDQ improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total amount of morphine administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral palsy development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mental or other delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Normal development status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of women receiving no prenatal care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Risk of acquiring less than adequate prenatal care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Proportion of infants born premature or with low birth-weights
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: EGG amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ReHo values in brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: amount of intraoperative sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microhardness of demineralized enamel surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete success rate of IOP lower than 21 mm Hg without medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualified success rate of IOP below 21 mm Hg with or without medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dyspnea at isotime
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SF-36 Vitality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in daily levodopa dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention